Clinical Trial Update: Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous CD19/BCMA dual-target CAR-T therapy for relapsed/refractory autoimmune diseases; currently recruiting at Beijing Boren Hospi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Idiopathic Inflammatory Myopathies
• Multiple Sclerosis
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Autologous CD19/BCMA dual-target CAR-T (CD19/BCMA dual-target chimeric antigen receptor T-cell)

Snippet

Sponsor: Beijing Boren Hospital | Conditions: Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis | Phase 1 | Status: RECRUITING